Analyze the mechanism of action and pharmacology of Teritusumab/Telivac

Teritusumab (Teclistamab-cqyv) is a representative bispecific monoclonal antibody. Its pharmacological design concept is fundamentally different from traditional anti-tumor drugs. Judging from overseas research and clinical application experience, the core value of this drug lies in the continuous recognition and elimination of multiple myeloma (MM) cells by redirecting the patient's own immune system, especially T cells.

At the molecular level, teritusumab can recognize two different target structures at the same time, one end of which binds to the CD3 receptor on the surface ofT cells, and the other end specifically binds to BCMA (B cell maturation antigen), which is highly expressed by multiple myeloma cells. BCMA is a molecule that has relatively limited expression in normal tissues but is continuously highly expressed in myeloma cells. This characteristic provides a good target basis for precise immunotherapy.

When teritusumab connectsT cells and tumor cells at the same time, it can form an "immune synapse" structure between the two, thereby prompting the T cells to be activated and release a variety of cytotoxic substances. This process does not rely on traditional antigen presentation pathways, making it possible to induce effective anti-tumor immune responses even in patients with compromised immune function or poor response to other immunotherapies.

From the perspective of pharmacological characteristics, teritusumab is a sustained immunomodulatory drug. Its role is not to eliminate tumors at one time, but to maintain immune pressure on myeloma cells through repeated activation ofT cells. This also explains why in overseas drug use practices, doctors often emphasize the importance of gradual administration and close monitoring of immune-related reactions to strike a balance between efficacy and safety.

Compared withCAR-T cell therapy, teritusumab does not require complicated cell collection and in vitro transformation processes. It is a "ready-made" immunotherapy drug and has relatively higher flexibility in use. But at the same time, its immune activation mechanism also determines that immune response-related discomfort may occur in the early stages of treatment, and it needs to be used standardizedly under the guidance of a professional medical team.

Keyword tags: teritusumab mechanism of action,Teclistamab pharmacology, Teclistamab principle, BCMA bispecific antibody, multiple myeloma immunotherapy, T cell redirection therapy

Reference materials:https://www.drugs.com/tecvayli.html